Tag Archives: Thomson Reuters
By Pharm Exec | Published: May 28, 2014
While some clinical trial sponsors have been driven out of the BRIC nations, a rise in rank for each country — Brazil, Russia, India, China — is expected over the next four years, indicating “blossoming healthcare budgets and markets that are ripe with opportunities for development”. According to a Thomson Reuters report, Overcoming Clinical Challenges in BRIC […]
By Guest Blogger | Published: June 29, 2011
Pharma expenditure on R&D has dropped to an estimated $68 billion, according to Thomson Reuters’ 2011 Pharmaceutical R&D Factbook. The three-year low demonstrates the receding trends of drug success, the amount of drugs entering Phase I and II trials and the number of new molecular entities (NMEs) launched in the global market.
By Ben Comer | Published: March 22, 2011
Two of the drugs named “most promising” in Thomson Reuters’ recent quarterly report hit snags in the US, despite European approval. Those two products – AstraZeneca’s Brilique (Brilinta in the US), a blood thinner, and Pharming’s Ruconest (Rhucin in the US) – were held up during FDA’s review process. Brilique (ticagrelor), AstraZeneca’s leading pipeline drug, […]